VAZOKLIN-DARNITSA

learn more

VAZOKLIN-DARNITSA

Agents reducing plasma levels of cholesterol and triglycerides.

HMG CoA reductase inhibitors.

Atorvastatin is a synthetic hypolipidemic medicinal product.

Indications.

Prevention of cardiovascular diseases.

In adult patients without clinically evident coronary heart disease, but with multiple risk factors for coronary heart disease such as age, smoking, hypertension, low HDL-C, or a family history of early coronary heart disease, Atorvastatin is indicated to:

  • Reduce the risk of myocardial infarction
  • Reduce the risk of stroke
  • Reduce the risk for revascularization procedures and angina

In patients with type 2 diabetes, and without clinically evident coronary heart disease, but with multiple risk factors for coronary heart disease such as retinopathy, albuminuria, smoking, or hypertension, Atorvastatin is indicated to:

  • Reduce the risk of myocardial infarction
  • Reduce the risk of stroke

In patients with clinically evident coronary heart disease, Atorvastatin is indicated to:

  • Reduce the risk of non-fatal myocardial infarction
  • Reduce the risk of fatal and non-fatal stroke
  • Reduce the risk for revascularization procedures
  • Reduce the risk of hospitalization for congestive heart failure
  • Reduce the risk of angina

Hyperlipidemia

  • As an adjunct to diet to reduce elevated total cholesterol, LDL cholesterol, apolipoprotein B, and triglyceride levels and to increase HDL cholesterol in patients with the primary hypercholesterolemia (heterozygous familial and nonfamilial) and mixed dyslipidemia (Fredrickson Types IIa and IIb);
  • As an adjunct to diet for the treatment of patients with elevated serum triglyceride levels (Fredrickson Type IV);
  • For the treatment of patients with the primary dysbetalipoproteinemia (Fredrickson Type III) who do not respond adequately to diet;
  • To reduce total cholesterol and LDL cholesterol in patients with the homozygous familial hypercholesterolemia as an adjunct to other lipid-lowering treatments (e.g., LDL apheresis) or if such treatments are unavailable;
  • As an adjunct to diet to reduce total cholesterol, LDL cholesterol and apolipoprotein B levels in boys and postmenarchal girls, 10 to 17 years of age, with the heterozygous familial hypercholesterolemia if after an adequate diet therapy the following findings are present:

a) LDL cholesterol remains 190 mg/dL or

b) LDL cholesterol remains 160 mg/dL and:

there is a positive family history of early cardiovascular disease or two or more other CVD risk factors are present in the pediatric patient.

 

 

More in instructions (Ukrainian version)
INN
Аtorvastatin
Form of release
Tablets
Appointment
Cardiovascular diseases
АТС class
C10А А 05
Specialized publications intended for medical institutions and doctors Limitations in obtaining information